The Combination Product Captisol-Enabled® Budesonide + Azelastine HCl Nasal Spray Provides Significant, Long-lasting Relief of Ocular Allergy Symptoms in Ragweed Allergic Patients Studied in an Environmental Exposure Chamber (EEC)

The Combination Product Captisol-Enabled® Budesonide + Azelastine HCl Nasal Spray Provides Significant, Long-lasting Relief of Ocular Allergy Symptoms in Ragweed Allergic Patients Studied in an Environmental Exposure Chamber (EEC)

Mean change from baseline (MCFB) in TOSS was significantly greater from placebo (p < 0.0001) from 40 mins post-dose until session end (10 h) for both Captisol-Enabled® Budesonide + Azelastine [MCFB:-1.3 ± 2.15] and Rhinocort Aqua®/Astelin® [MCFB:-1.3 ± 1.79].Captisol-Enabled® Budesonide + A...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of allergy and clinical immunology 2009-02, Vol.123 (2), p.S130-S130
Hauptverfasser: Patel, P, Salapatek, A, D'Angelo, P, Bates, M, Patel, D, Zimmerer, R, Pipkin, J.D
Format: Artikel
Sprache:eng
Schlagworte:
Allergies
Allergy and Immunology
Drug therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S130
container_issue 2
container_start_page S130
container_title Journal of allergy and clinical immunology
container_volume 123
creator Patel, P
Salapatek, A
D'Angelo, P
Bates, M
Patel, D
Zimmerer, R
Pipkin, J.D
description Mean change from baseline (MCFB) in TOSS was significantly greater from placebo (p < 0.0001) from 40 mins post-dose until session end (10 h) for both Captisol-Enabled® Budesonide + Azelastine [MCFB:-1.3 ± 2.15] and Rhinocort Aqua®/Astelin® [MCFB:-1.3 ± 1.79].Captisol-Enabled® Budesonide + Azelastine provided the same or greater numerical TOSS relief (did not reach statistical difference) than Rhinocort Aqua®/Astelin® for 13/14 time points and longer-lasting relief of Red/Burning eyes for the duration of the study (10 h).
doi_str_mv 10.1016/j.jaci.2008.12.482
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1504845076</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674908029047</els_id><sourcerecordid>3239632941</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2286-d90cedf7603ea466c1021b044be78506edc402889345c6323fd01fbe0edb86053</originalsourceid><addsrcrecordid>eNp9Ut2K1DAULqLguvoCXgW8UbTjSfoPIoylusLgLjvrdUjT09mMaVKTdnR8KB_Cl_E1TJkFwQuvQvh-8p18J4qeUlhRoPnr_WovpFoxgHJF2Sot2b3ojEJVxHnJsvvRGUBF47xIq4fRI-_3EO5JWZ1Fv29ukdR2aJURk7KGXDnbzXIitRgn5a2OGyNajd2vn-Td3KG3RnVIXpL1D9TCT8oguag1-SS80GQ7OnFcLA6B5MlW7YzqlRRmekU21uzik2RHrlEr7IntyaWctXBkrTW63ZFsj8M42cETZci12H1D7O4wJclViIhmCsbT3KmABJIwpDEH5awZAhQyNN9H62cXproVQ4uOPG-a-sXj6EEvtMcnd-d59Pl9c1NfxJvLDx_r9SaWjJV53FUgseuLHBIUaZ5LCoy2kKYtFmUGOXYyBVaWVZJmMk9Y0ndA-xYBu7bMIUvOo2cn39HZrzP6ie_t7Ex4ktMM0jLNoMgDi51Y0lnvHfZ8dGoQ7sgp8KVQvudLoXwplFPGQ6FB9OYkwpD_oNBxL8N3hLzKoZx4Z9X_5W__kUutTChHf8Ej-r8xuWcc-HbZmGVhoARWQVokfwBpasH7</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504845076</pqid></control><display><type>article</type><title>The Combination Product Captisol-Enabled® Budesonide + Azelastine HCl Nasal Spray Provides Significant, Long-lasting Relief of Ocular Allergy Symptoms in Ragweed Allergic Patients Studied in an Environmental Exposure Chamber (EEC)</title><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Patel, P ; Salapatek, A ; D'Angelo, P ; Bates, M ; Patel, D ; Zimmerer, R ; Pipkin, J.D</creator><creatorcontrib>Patel, P ; Salapatek, A ; D'Angelo, P ; Bates, M ; Patel, D ; Zimmerer, R ; Pipkin, J.D</creatorcontrib><description>Mean change from baseline (MCFB) in TOSS was significantly greater from placebo (p &lt; 0.0001) from 40 mins post-dose until session end (10 h) for both Captisol-Enabled® Budesonide + Azelastine [MCFB:-1.3 ± 2.15] and Rhinocort Aqua®/Astelin® [MCFB:-1.3 ± 1.79].Captisol-Enabled® Budesonide + Azelastine provided the same or greater numerical TOSS relief (did not reach statistical difference) than Rhinocort Aqua®/Astelin® for 13/14 time points and longer-lasting relief of Red/Burning eyes for the duration of the study (10 h).</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2008.12.482</identifier><language>eng</language><publisher>St. Louis: Mosby, Inc</publisher><subject>Allergies ; Allergy and Immunology ; Drug therapy</subject><ispartof>Journal of allergy and clinical immunology, 2009-02, Vol.123 (2), p.S130-S130</ispartof><rights>American Academy of Allergy, Asthma &amp; Immunology</rights><rights>2009 American Academy of Allergy, Asthma &amp; Immunology</rights><rights>Copyright Elsevier Limited Feb 2009</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2286-d90cedf7603ea466c1021b044be78506edc402889345c6323fd01fbe0edb86053</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0091674908029047$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids></links><search><creatorcontrib>Patel, P</creatorcontrib><creatorcontrib>Salapatek, A</creatorcontrib><creatorcontrib>D'Angelo, P</creatorcontrib><creatorcontrib>Bates, M</creatorcontrib><creatorcontrib>Patel, D</creatorcontrib><creatorcontrib>Zimmerer, R</creatorcontrib><creatorcontrib>Pipkin, J.D</creatorcontrib><title>The Combination Product Captisol-Enabled® Budesonide + Azelastine HCl Nasal Spray Provides Significant, Long-lasting Relief of Ocular Allergy Symptoms in Ragweed Allergic Patients Studied in an Environmental Exposure Chamber (EEC)</title><title>Journal of allergy and clinical immunology</title><description>Mean change from baseline (MCFB) in TOSS was significantly greater from placebo (p &lt; 0.0001) from 40 mins post-dose until session end (10 h) for both Captisol-Enabled® Budesonide + Azelastine [MCFB:-1.3 ± 2.15] and Rhinocort Aqua®/Astelin® [MCFB:-1.3 ± 1.79].Captisol-Enabled® Budesonide + Azelastine provided the same or greater numerical TOSS relief (did not reach statistical difference) than Rhinocort Aqua®/Astelin® for 13/14 time points and longer-lasting relief of Red/Burning eyes for the duration of the study (10 h).</description><subject>Allergies</subject><subject>Allergy and Immunology</subject><subject>Drug therapy</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNp9Ut2K1DAULqLguvoCXgW8UbTjSfoPIoylusLgLjvrdUjT09mMaVKTdnR8KB_Cl_E1TJkFwQuvQvh-8p18J4qeUlhRoPnr_WovpFoxgHJF2Sot2b3ojEJVxHnJsvvRGUBF47xIq4fRI-_3EO5JWZ1Fv29ukdR2aJURk7KGXDnbzXIitRgn5a2OGyNajd2vn-Td3KG3RnVIXpL1D9TCT8oguag1-SS80GQ7OnFcLA6B5MlW7YzqlRRmekU21uzik2RHrlEr7IntyaWctXBkrTW63ZFsj8M42cETZci12H1D7O4wJclViIhmCsbT3KmABJIwpDEH5awZAhQyNN9H62cXproVQ4uOPG-a-sXj6EEvtMcnd-d59Pl9c1NfxJvLDx_r9SaWjJV53FUgseuLHBIUaZ5LCoy2kKYtFmUGOXYyBVaWVZJmMk9Y0ndA-xYBu7bMIUvOo2cn39HZrzP6ie_t7Ex4ktMM0jLNoMgDi51Y0lnvHfZ8dGoQ7sgp8KVQvudLoXwplFPGQ6FB9OYkwpD_oNBxL8N3hLzKoZx4Z9X_5W__kUutTChHf8Ej-r8xuWcc-HbZmGVhoARWQVokfwBpasH7</recordid><startdate>20090201</startdate><enddate>20090201</enddate><creator>Patel, P</creator><creator>Salapatek, A</creator><creator>D'Angelo, P</creator><creator>Bates, M</creator><creator>Patel, D</creator><creator>Zimmerer, R</creator><creator>Pipkin, J.D</creator><general>Mosby, Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20090201</creationdate><title>The Combination Product Captisol-Enabled® Budesonide + Azelastine HCl Nasal Spray Provides Significant, Long-lasting Relief of Ocular Allergy Symptoms in Ragweed Allergic Patients Studied in an Environmental Exposure Chamber (EEC)</title><author>Patel, P ; Salapatek, A ; D'Angelo, P ; Bates, M ; Patel, D ; Zimmerer, R ; Pipkin, J.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2286-d90cedf7603ea466c1021b044be78506edc402889345c6323fd01fbe0edb86053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Allergies</topic><topic>Allergy and Immunology</topic><topic>Drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Patel, P</creatorcontrib><creatorcontrib>Salapatek, A</creatorcontrib><creatorcontrib>D'Angelo, P</creatorcontrib><creatorcontrib>Bates, M</creatorcontrib><creatorcontrib>Patel, D</creatorcontrib><creatorcontrib>Zimmerer, R</creatorcontrib><creatorcontrib>Pipkin, J.D</creatorcontrib><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Patel, P</au><au>Salapatek, A</au><au>D'Angelo, P</au><au>Bates, M</au><au>Patel, D</au><au>Zimmerer, R</au><au>Pipkin, J.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Combination Product Captisol-Enabled® Budesonide + Azelastine HCl Nasal Spray Provides Significant, Long-lasting Relief of Ocular Allergy Symptoms in Ragweed Allergic Patients Studied in an Environmental Exposure Chamber (EEC)</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><date>2009-02-01</date><risdate>2009</risdate><volume>123</volume><issue>2</issue><spage>S130</spage><epage>S130</epage><pages>S130-S130</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>Mean change from baseline (MCFB) in TOSS was significantly greater from placebo (p &lt; 0.0001) from 40 mins post-dose until session end (10 h) for both Captisol-Enabled® Budesonide + Azelastine [MCFB:-1.3 ± 2.15] and Rhinocort Aqua®/Astelin® [MCFB:-1.3 ± 1.79].Captisol-Enabled® Budesonide + Azelastine provided the same or greater numerical TOSS relief (did not reach statistical difference) than Rhinocort Aqua®/Astelin® for 13/14 time points and longer-lasting relief of Red/Burning eyes for the duration of the study (10 h).</abstract><cop>St. Louis</cop><pub>Mosby, Inc</pub><doi>10.1016/j.jaci.2008.12.482</doi></addata></record>
fulltext fulltext
identifier ISSN: 0091-6749
ispartof Journal of allergy and clinical immunology, 2009-02, Vol.123 (2), p.S130-S130
issn 0091-6749
1097-6825
language eng
recordid cdi_proquest_journals_1504845076
source Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Allergies
Allergy and Immunology
Drug therapy
title The Combination Product Captisol-Enabled® Budesonide + Azelastine HCl Nasal Spray Provides Significant, Long-lasting Relief of Ocular Allergy Symptoms in Ragweed Allergic Patients Studied in an Environmental Exposure Chamber (EEC)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T04%3A24%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Combination%20Product%20Captisol-Enabled%C2%AE%20Budesonide%20+%20Azelastine%20HCl%20Nasal%20Spray%20Provides%20Significant,%20Long-lasting%20Relief%20of%20Ocular%20Allergy%20Symptoms%20in%20Ragweed%20Allergic%20Patients%20Studied%20in%20an%20Environmental%20Exposure%20Chamber%20(EEC)&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Patel,%20P&rft.date=2009-02-01&rft.volume=123&rft.issue=2&rft.spage=S130&rft.epage=S130&rft.pages=S130-S130&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2008.12.482&rft_dat=%3Cproquest_cross%3E3239632941%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1504845076&rft_id=info:pmid/&rft_els_id=S0091674908029047&rfr_iscdi=true